Deregulation on branded and generic drugs price and its effect: a study of Chinese pharmaceutical market

被引:0
|
作者
Liu, Lu [1 ]
机构
[1] St Bonaventure Univ, Sch Business, Dept Mkt, St Bonaventure, NY 14778 USA
关键词
Health care quality; Health policy; Statistics; Quality; Quantitative research; Public health regulations; COMPETITION; ENTRY;
D O I
10.1108/IJHG-12-2021-0123
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
PurposeThis research studies the effect of deregulation of price cap in pharmaceutical market. Price regulation (either through price cap or reference price) is common practice in the pharmaceutical market but recently there are increasing voices calling for deregulation claiming that deregulation could help in lowering drug price and increase revenue of pharmaceutical firms. Upon those callings, Chinese government removed the price cap regulation in June 2015. The author uses this natural policy experiment to study this effect.Design/methodology/approachIn this study, the author applied the interrupted time series analysis (ITSA) on the revenue data of nine categories of both generic and branded drugs in China from March 2011 to August 2016 (the time frame includes both before and after of the initialization of the deregulation) and analyzed the effect of deregulation.FindingsThe results showed that, whether the revenue of drugs will increase or decrease after the deregulation of price cap depends on the level of competition and the change of patterns of the branded and generic drugs are different. When HHI (Herfindahl-Hirschman index) is sufficiently low (competition is high), revenue does not change as a result of deregulation, when HHI is moderately low (moderate competition), revenue from generic drugs will decrease significantly and revenue from branded drugs will increase significantly, and when HHI is high (low competition), revenue from generic drugs will increase significantly and revenue from branded drugs will decrease significantly.Originality/valueThis is a unique study with a unique data set. Most previous studies focus on regulation of drug price and analyze how this may affect drug revenue; however, this is a natural policy experiment of de-regulation. Moreover, previously most studies focus on reference pricing regulation and this is price-cap, a different mechanism that is rarely studied. The originality/value is high of this article.
引用
收藏
页码:17 / 30
页数:14
相关论文
共 50 条
  • [1] Price and Quality in the Generic Pharmaceutical Market
    Teasdale, Ben
    Light, David
    Schulman, Kevin A.
    [J]. CIRCULATION, 2022, 145 (16) : 1185 - 1187
  • [2] ESTIMATES OF THE PRICE ELASTICITY OF SWITCHING BETWEEN BRANDED AND GENERIC DRUGS
    Terrizzi, Sabrina
    Meyerhoefer, Chad
    [J]. CONTEMPORARY ECONOMIC POLICY, 2020, 38 (01) : 94 - 108
  • [3] Price regulation and generic competition in the pharmaceutical market
    Dalen D.M.
    Strøm S.
    Haabeth T.
    [J]. The European Journal of Health Economics, 2006, 7 (3) : 208 - 214
  • [4] Price competition in the Chinese pharmaceutical market
    Wang Y.R.
    [J]. International Journal of Health Care Finance and Economics, 2006, 6 (2): : 119 - 129
  • [5] THE PRICE RISE OF GENERIC DRUGS IN US MARKET
    Joshi, D.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A33 - A33
  • [6] COMPARATIVE STUDY OF THE EFFICIENCY OF BRANDED AND GENERIC DRUGS ON ANAEMIA
    Devi, M. Gayathri
    Jyothirmai, T.
    Savithri, M.
    [J]. INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 5 (01): : 664 - 672
  • [7] Competition between Branded and Generic Drugs in Austria: Evidence from the Market for ACE Inhibitors
    Mahlich, J. C.
    Stadler, I.
    [J]. GESUNDHEITSWESEN, 2012, 74 (01) : 23 - 28
  • [8] The price and mark up of pharmaceutical drugs supplied on the black market
    Hulme, Shann
    Hughes, Caitlin Elizabeth
    Nielsen, Suzanne
    [J]. INTERNATIONAL JOURNAL OF DRUG POLICY, 2020, 76
  • [9] THE IMPACT OF GENERIC DRUG ENTRY ON MARKET SHARES AND PRICES OF BRAND-NAME DRUGS-EVIDENCE FROM CHINESE PHARMACEUTICAL MARKET
    Chen, J.
    Tian, Y.
    Shi, L. W.
    [J]. VALUE IN HEALTH, 2018, 21 : S9 - S9
  • [10] The impact of price-cap regulations on market entry by generic pharmaceutical firms
    Zhang, Wei
    Sun, Huiying
    Guh, Daphne
    Anis, Aslam H.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2017, 17 (02) : 231 - 238